AAAAAA

   
Results: 1-25 | 26-50 | 51-55
Results: 1-25/55
DELAYED EMESIS FOLLOWING ANTICANCER CHEMOTHERAPY
Authors: KRIS MG ROILA F DEMULDER PHM MARTY M
Citation: Mg. Kris et al., DELAYED EMESIS FOLLOWING ANTICANCER CHEMOTHERAPY, Supportive care in cancer, 6(3), 1998, pp. 228-232
CONSENSUS REGARDING MULTIPLE DAY AND RESCUE ANTIEMETIC THERAPY
Authors: DEMULDER PHM ROILA F KRIS MG MARTY MM
Citation: Phm. Demulder et al., CONSENSUS REGARDING MULTIPLE DAY AND RESCUE ANTIEMETIC THERAPY, Supportive care in cancer, 6(3), 1998, pp. 248-252
PREVENTION OF CHEMOTHERAPY-INDUCED AND RADIOTHERAPY-INDUCED EMESIS - RESULTS OF THE PERUGIA CONSENSUS CONFERENCE
Authors: ROILA F DELFAVERO A GRALLA RJ TONATO M AAPRO MS ANDREWS PLR BALLATORI E DEMULDER PHM DICATO MA DUBOIS A FEYER PC GANDARA DR GRALLA RJ GRALLA RJ GROSHEN S GRUNBERG SM HERRSTEDT J HESKETH PJ JOSS RA KRIS MG MARTY MM MORROW GR NAYLOR RJ OLVER IN SMYTH JF SPITZER TR STEWART A
Citation: F. Roila et al., PREVENTION OF CHEMOTHERAPY-INDUCED AND RADIOTHERAPY-INDUCED EMESIS - RESULTS OF THE PERUGIA CONSENSUS CONFERENCE, Annals of oncology, 9(8), 1998, pp. 811-819
SEMINOMA AND SARCOIDOSIS - A CAUSE FOR FALSE-POSITIVE MEDIASTINAL UPTAKE IN PET - RESPONSE
Authors: TJANHEIJNEN VCG VLASVELD LT DEMULDER PHM
Citation: Vcg. Tjanheijnen et al., SEMINOMA AND SARCOIDOSIS - A CAUSE FOR FALSE-POSITIVE MEDIASTINAL UPTAKE IN PET - RESPONSE, Annals of oncology, 9(8), 1998, pp. 924-924
COINCIDENCE OF SEMINOMA AND SARCOIDOSIS - A MYTH OR FACT
Authors: TJANHEIJNEN VCG VLASVELD LT PERNET EPPM PAUWELS P DEMULDER PHM
Citation: Vcg. Tjanheijnen et al., COINCIDENCE OF SEMINOMA AND SARCOIDOSIS - A MYTH OR FACT, Annals of oncology, 9(3), 1998, pp. 321-325
A DOSE-FINDING STUDY OF PACLITAXEL (TAXOL) ADDED TO FIXED DOSES OF BLEOMYCIN, ETOPOSIDE, CISPLATIN (BEP) IN PATIENTS WITH ADVERSE PROGNOSISGERM-CELL CANCER OR CARCINOMA OF UNKNOWN PRIMARY (CUP)
Authors: LOUWERENS M SCHORNAGEL J DEMULDER PHM DEWIT R
Citation: M. Louwerens et al., A DOSE-FINDING STUDY OF PACLITAXEL (TAXOL) ADDED TO FIXED DOSES OF BLEOMYCIN, ETOPOSIDE, CISPLATIN (BEP) IN PATIENTS WITH ADVERSE PROGNOSISGERM-CELL CANCER OR CARCINOMA OF UNKNOWN PRIMARY (CUP), Annals of oncology, 9, 1998, pp. 366-366
FILGRASTIM DURING COMBINATION CHEMOTHERAPY OF PATIENTS WITH POOR-PROGNOSIS METASTATIC GERM-CELL MALIGNANCY
Authors: FOSSA SD KAYE SB MEAD GM CULLEN M DEWIT R BODROGI I VANGROENINGEN CJ DEMULDER PHM STENNING S LALLEMAND E DEPRIJCK L COLLETTE L
Citation: Sd. Fossa et al., FILGRASTIM DURING COMBINATION CHEMOTHERAPY OF PATIENTS WITH POOR-PROGNOSIS METASTATIC GERM-CELL MALIGNANCY, Journal of clinical oncology, 16(2), 1998, pp. 716-724
PHASE I II RADIOIMMUNOTHERAPY WITH I-131-LABELED CHIMERIC MONOCLONAL-ANTIBODY CG250 IN PATIENTS WITH METASTASIZED RENAL-CELL CARCINOMA/
Authors: STEFFENS MG BOERMAN OC OOSTERWIJK E OYEN WJG DEMULDER PHM WITJES JA OOSTERHOF GON DEBRUYNE FMJ CORSTENS FHM
Citation: Mg. Steffens et al., PHASE I II RADIOIMMUNOTHERAPY WITH I-131-LABELED CHIMERIC MONOCLONAL-ANTIBODY CG250 IN PATIENTS WITH METASTASIZED RENAL-CELL CARCINOMA/, The Journal of nuclear medicine, 39(5), 1998, pp. 1089-1089
RADIOIMMUNOTHERAPY WITH I-131 CG250 MONOCLONAL-ANTIBODY IN PATIENTS WITH METASTASIZED RCC, A PHASE I II STUDY/
Authors: STEFFENS MG BOERMAN OC OYEN WJG DEMULDER PHM WITJES JA OOSTERHOF GON CORSTENS FHM DEBRUYNE FMJ OOSTERWIJK E
Citation: Mg. Steffens et al., RADIOIMMUNOTHERAPY WITH I-131 CG250 MONOCLONAL-ANTIBODY IN PATIENTS WITH METASTASIZED RCC, A PHASE I II STUDY/, The Journal of urology, 159(5), 1998, pp. 562-562
SERUM ALPHA-FETOPROTEIN SURGE AFTER THE INITIATION OF CHEMOTHERAPY FOR NONSEMINOMATOUS TESTICULAR CANCER HAS AN ADVERSE PROGNOSTIC-SIGNIFICANCE
Authors: DEWIT R COLLETTE L SYLVESTER R DEMULDER PHM SLEIJFER DT HUININK WWT KAYE SB VANOOSTEROM AT BOVEN E STOTER G
Citation: R. Dewit et al., SERUM ALPHA-FETOPROTEIN SURGE AFTER THE INITIATION OF CHEMOTHERAPY FOR NONSEMINOMATOUS TESTICULAR CANCER HAS AN ADVERSE PROGNOSTIC-SIGNIFICANCE, British Journal of Cancer, 78(10), 1998, pp. 1350-1355
EORTC PHASE-II STUDY OF DAILY ORAL LINOMIDE IN METASTATIC RENAL-CELL CARCINOMA PATIENTS WITH GOOD PROGNOSTIC FACTORS
Authors: DEWIT R PAWINSKY A STOTER G VANOOSTEROM AT FOSSA SD PARIDAENS R SVEDBERG A DEMULDER PHM
Citation: R. Dewit et al., EORTC PHASE-II STUDY OF DAILY ORAL LINOMIDE IN METASTATIC RENAL-CELL CARCINOMA PATIENTS WITH GOOD PROGNOSTIC FACTORS, European journal of cancer, 33(3), 1997, pp. 493-495
AN EORTC PHASE-II STUDY OF THE EFFICACY AND SAFETY OF LINOMIDE IN THETREATMENT OF ADVANCED RENAL-CELL CARCINOMA
Authors: PAWINSKI A VANOOSTEROM AT DEWIT R FOSSA S CROLES J SVEDBERG A LENTZ MA DEMULDER PHM
Citation: A. Pawinski et al., AN EORTC PHASE-II STUDY OF THE EFFICACY AND SAFETY OF LINOMIDE IN THETREATMENT OF ADVANCED RENAL-CELL CARCINOMA, European journal of cancer, 33(3), 1997, pp. 496-499
PHASE-II STUDY OF WEEKLY HIGH-DOSE CISPLATIN FOR 6 CYCLES IN PATIENTSWITH LOCALLY ADVANCED SQUAMOUS-CELL CARCINOMA OF THE HEAD AND NECK
Authors: PLANTING AST DEMULDER PHM DEGRAEFF A VERWEIJ J
Citation: Ast. Planting et al., PHASE-II STUDY OF WEEKLY HIGH-DOSE CISPLATIN FOR 6 CYCLES IN PATIENTSWITH LOCALLY ADVANCED SQUAMOUS-CELL CARCINOMA OF THE HEAD AND NECK, European journal of cancer, 33(1), 1997, pp. 61-65
TREATMENT IN GERM-CELL TUMORS - STATE-OF-THE-ART
Authors: TJANHEIJNEN VCG OOSTERHOF GON DEWIT R DEMULDER PHM
Citation: Vcg. Tjanheijnen et al., TREATMENT IN GERM-CELL TUMORS - STATE-OF-THE-ART, European journal of surgical oncology, 23(2), 1997, pp. 110-117
RANDOMIZED TRIAL OF BLEOMYCIN, ETOPOSIDE, AND CISPLATIN COMPARED WITHBLEOMYCIN, ETOPOSIDE, AND CARBOPLATIN IN GOOD-PROGNOSIS METASTATIC NONSEMINOMATOUS GERM-CELL CANCER - A MULTIINSTITUTIONAL MEDICAL-RESEARCH-COUNCIL -ORGANIZATION-FOR-RESEARCH-AND-TREATMENT-OF-CANCER TRIAL
Authors: HORWICH A SLEIJFER DT FOSSA SD KAYE SB OLIVER RTD CULLEN MH MEAD GM DEWIT R DEMULDER PHM DEARNALEY DP COOK PA SYLVESTER RJ STENNING SP
Citation: A. Horwich et al., RANDOMIZED TRIAL OF BLEOMYCIN, ETOPOSIDE, AND CISPLATIN COMPARED WITHBLEOMYCIN, ETOPOSIDE, AND CARBOPLATIN IN GOOD-PROGNOSIS METASTATIC NONSEMINOMATOUS GERM-CELL CANCER - A MULTIINSTITUTIONAL MEDICAL-RESEARCH-COUNCIL -ORGANIZATION-FOR-RESEARCH-AND-TREATMENT-OF-CANCER TRIAL, Journal of clinical oncology, 15(5), 1997, pp. 1844-1852
INTERNATIONAL GERM-CELL CONSENSUS CLASSIFICATION - A PROGNOSTIC FACTOR-ERASED STAGING SYSTEM FOR METASTATIC GERM-CELL CANCERS
Authors: MEAD GM STENNING SP COOK P FOSSA SD HORWICH A KAYE SB OLIVER RTD DEMULDER PHM DEWIT R STOTER G SYLVESTER RJ BAJORIN DF BOSL GJ MAZUMDAR M NICHOLS CR AMATO R PIZZOCARO G DROZ JP KRAMAR A DAUGAARD G CORTESFUNES H PAZARES L LEVI JA COLLS BM HARVEY VJ COPPIN C
Citation: Gm. Mead et al., INTERNATIONAL GERM-CELL CONSENSUS CLASSIFICATION - A PROGNOSTIC FACTOR-ERASED STAGING SYSTEM FOR METASTATIC GERM-CELL CANCERS, Journal of clinical oncology, 15(2), 1997, pp. 594-603
CHEMOIMMUNOTHERAPY WITH BLEOMYCIN, VINCRISTINE, LOMUSTINE, DACARBAZINE (BOLD) PLUS INTERFERON-ALPHA FOR METASTATIC MELANOMA - A MULTICENTERPHASE-II STUDY
Authors: PUNT CJA VANHERPEN CML JANSEN RLH VREUGDENHIL G MULLER EW DEMULDER PHM
Citation: Cja. Punt et al., CHEMOIMMUNOTHERAPY WITH BLEOMYCIN, VINCRISTINE, LOMUSTINE, DACARBAZINE (BOLD) PLUS INTERFERON-ALPHA FOR METASTATIC MELANOMA - A MULTICENTERPHASE-II STUDY, British Journal of Cancer, 76(2), 1997, pp. 266-269
PHASE IB STUDY OF DOXORUBICIN IN COMBINATION WITH THE MULTIDRUG-RESISTANCE REVERSING AGENT S9788 IN ADVANCED COLORECTAL AND RENAL-CELL CANCER
Authors: PUNT CJA VOEST EE TUENI E VANOOSTEROM AT BACKX A DEMULDER PHM HECQUET B LUCAS C GERARD B BLEIBERG H
Citation: Cja. Punt et al., PHASE IB STUDY OF DOXORUBICIN IN COMBINATION WITH THE MULTIDRUG-RESISTANCE REVERSING AGENT S9788 IN ADVANCED COLORECTAL AND RENAL-CELL CANCER, British Journal of Cancer, 76(10), 1997, pp. 1376-1381
TUMOR-MARKER CONCENTRATION AT THE START OF CHEMOTHERAPY IS A STRONGERPREDICTOR OF TREATMENT FAILURE THAN MARKER HALF-LIFE - A STUDY IN PATIENTS WITH DISSEMINATED NONSEMINOMATOUS TESTICULAR CANCER
Authors: DEWIT R SYLVESTER R TSITSA C DEMULDER PHM SLEYFER DT HUININK WWT KAYE SB VANOOSTEROM AT BOVEN E VERMEYLEN K STOTER G
Citation: R. Dewit et al., TUMOR-MARKER CONCENTRATION AT THE START OF CHEMOTHERAPY IS A STRONGERPREDICTOR OF TREATMENT FAILURE THAN MARKER HALF-LIFE - A STUDY IN PATIENTS WITH DISSEMINATED NONSEMINOMATOUS TESTICULAR CANCER, British Journal of Cancer, 75(3), 1997, pp. 432-435
PHASE-II STUDY ON MITOXANTRONE IN ADENOID CYSTIC CARCINOMAS OF THE HEAD AND NECK
Authors: VERWEIJ J DEMULDER PHM DEGRAEFF A VERMORKEN JB WILDIERS J KERGER J SCHORNAGEL J COGNETTI F KIRKPATRICK A SAHMOUD T LEFEBVRE JL
Citation: J. Verweij et al., PHASE-II STUDY ON MITOXANTRONE IN ADENOID CYSTIC CARCINOMAS OF THE HEAD AND NECK, Annals of oncology, 7(8), 1996, pp. 867-869
THE MANAGEMENT OF GRANULOSA-CELL TUMOR OF THE OVARY - A CASE-HISTORY
Authors: VERHAGEN CAHHVM VANHOESEL QGCM SCHIJF CPT DEMULDER PHM
Citation: Cahhvm. Verhagen et al., THE MANAGEMENT OF GRANULOSA-CELL TUMOR OF THE OVARY - A CASE-HISTORY, Annals of oncology, 7(5), 1996, pp. 521-524
ANALYSIS OF CUMULATIVE PROBABILITIES SHOWS THAT THE EFFICACY OF 5HT(3) ANTAGONIST PROPHYLAXIS IS NOT MAINTAINED
Authors: DEWIT R SCHMITZ PIM VERWEIJ J DEBOERDENNERT M DEMULDER PHM PLANTING AST VANDERBURG MEL STOTER G
Citation: R. Dewit et al., ANALYSIS OF CUMULATIVE PROBABILITIES SHOWS THAT THE EFFICACY OF 5HT(3) ANTAGONIST PROPHYLAXIS IS NOT MAINTAINED, Journal of clinical oncology, 14(2), 1996, pp. 644-651
GEMCITABINE - A PHASE-II STUDY IN PATIENTS WITH ADVANCED RENAL-CANCER
Authors: DEMULDER PHM WEISSBACH L JAKSE G OSIEKA R BLATTER J
Citation: Phm. Demulder et al., GEMCITABINE - A PHASE-II STUDY IN PATIENTS WITH ADVANCED RENAL-CANCER, Cancer chemotherapy and pharmacology, 37(5), 1996, pp. 491-495
EXPERIMENTAL AND CLINICAL EFFICACY OF 2',2'-DIFLUORODEOXYCYTIDINE (GEMCITABINE) AGAINST RENAL-CELL CARCINOMA
Authors: ROHDE D DEMULDER PHM WEISSBACH L OSIEKA R BLATTER J JAKSE G
Citation: D. Rohde et al., EXPERIMENTAL AND CLINICAL EFFICACY OF 2',2'-DIFLUORODEOXYCYTIDINE (GEMCITABINE) AGAINST RENAL-CELL CARCINOMA, Oncology, 53(6), 1996, pp. 476-481
OPTIMAL-CONTROL OF ACUTE CISPLATIN-INDUCED EMESIS
Authors: VERWEIJ J DEWIT R DEMULDER PHM
Citation: J. Verweij et al., OPTIMAL-CONTROL OF ACUTE CISPLATIN-INDUCED EMESIS, Oncology, 53, 1996, pp. 56-64
Risultati: 1-25 | 26-50 | 51-55